. Get Fulcrum Therapeutics Inc (FULC:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. Research salary, company info, career paths, and top skills for Manager, Clinical Data Management View the job description, responsibilities and qualifications for this position.
Fulcrum Therapeutics ( NASDAQ:FULC - Get Rating) last posted its earnings results on Monday, May 9th. Our approach to drug discovery generates significant insights into disease biology and allows us to think creatively about the best way to modulate and balance gene expression. Initial data from the first subjects to receive a 6 mg dose of FTX-6058, an oral HbF inducer, showed a rapid and robust induction of HbF, and subjects achieved increases of up to 6.3% over . ET to discuss the Company's first quarter 2022 recent business highlights and financial results. The firm has a market capitalization of $312.08 million, a price-to-earnings ratio of -3.20 and a beta of 2.52. As of June 23, 2022, Fulcrum Therapeutics Inc had a $201.0 million market capitalization, compared to the Biotechnology & Medical Research median of $107.3 million. Fulcrum Therapeutics's next ex-dividend date is May 7, 2020.
Medable Inc. 1+ Downloads.
. 2022-06-30 - Amalgamated Bank has filed a 13F-HR form disclosing ownership of 3,324 shares of Fulcrum Therapeutics Inc (US:FULC) with total holdings valued at $79,000 USD as of 2022-03-31. Glassdoor gives you an inside look at what it's like to work at Fulcrum Therapeutics, including salaries, reviews, office photos, and more. Fulcrum's proprietary product engine identifies drug targets which can modulate gene expression to treat the known root cause of . 02139-4216. Fulcrum Therapeutics. Morgan . United States. This suggests a possible upside of 544.3% from the stock's current price. Contact: Dee Smith Executive Director, Corporate Communications Fulcrum Therapeutics (202) 746-1324 Tired of arriving late to the Big Returns Party? June 23, 2020. Contact: REACH . Data safety. Fulcrum Therapeutics Inc. (NASDAQ:FULC) shares, rose in value on Thursday, 06/02/22, with the stock price up by 8.67% to the previous day's close as strong demand from buyers drove the stock to $7.52. The stock has a market capitalization of $200.98 million, a PE ratio of -2.06 and a beta of 2.55. Fulcrum Therapeutics Inc only started trading within the last year so does not have performance data for the past year. Its product candidate, losmapimod, is a small molecule that was developed for the treatment of FSHD, a muscle-wasting disorder that . Accounting Manager at Fulcrum Therapeutics Boston, Massachusetts, United States 363 connections. Fulcrum . Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum . Fulcrum Therapeutics, Inc. (FULC) came out with a quarterly loss of $0.60 per share versus the Zacks Consensus Estimate of a loss of $0.65. Fulcrum Therapeutics Employees: 122 | Industry: Biotechnology, Gene Regulation, Science and Engineering | Founded: 2016 . About Fulcrum Therapeutics Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Bryan Stuart was named president and chief executive officer of Fulcrum Therapeutics in March 2021. Address. The company reported ($0.64) earnings per share (EPS) for the . Contact: REACH trial information clinicaltrials@fulcrumtx.com Investors Stephanie Ascher Stern Investor Relations, Inc. stephanie.ascher@sternir.com 212-362-1200 Media Dee Smith 26 Landsdowne St. Cambridge, MA. We have developed a rigorous assessment and selection process to determine which of the approximately 7,000 rare, genetically defined diseases we intend to evaluate in drug target identification activities. Do the numbers hold clues to what lies ahead for the . Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. The randomized, double-blind, placebo-controlled, multi-national Phase 3 trial will enroll approximately 230 adults at over 30 sites in North . Issuer Name and Ticker or Trading Symbol Fulcrum Therapeutics, Inc. [FULC] 5. Relationship of Reporting Person(s) to Issuer . 8 Wall Street research analysts have issued 12 month price objectives for Fulcrum Therapeutics' stock. Fulcrum Therapectics to develop new medicines to deliver a new future for patients and their families by transforming gene regulation in disease. Fulcrum Therapeutics, Inc. 26 Landsdowne Street Cambridge, MA 02139. About Fulcrum Therapeutics. View Top Employees from Fulcrum Therapeutics Find contact info for Fulcrum Therapeutics employees The next quarterly earnings date for Fulcrum Therapeutics is scheduled on August 10, 2022.
Cambridge, MA. The 1-year high price for the company's stock is recorded $24.79 on 04/05/22, with the lowest value was $3.21 for the same time period, recorded on 06/10/22. This is the Fulcrum Therapeutics company profile. We can divert our attention to . Everyone. The company develops a proprietary product engine that employs to identify and validate cellular drug targets that can modulate gene expression. and may address the renin-angiotensin system imbalance that is believed to contribute to key morbidities in COVID-19 patients. They currently have a . The shares were sold at an average price of $24.02, for a total value of $135,256.62. PepGen Appoints Michelle Mellion, M.D., as Senior Vice President, Head of Clinical Development. Fulcrum's two lead programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral . arrow_forward. Fulcrum Therapeutics Office Locations Fulcrum Therapeutics has an office in Cambridge Open Map View Cambridge, MA, US (HQ) 26 Landsdowne St Show all (1) Report incorrect company information Fulcrum Therapeutics Financials and Metrics Fulcrum Therapeutics Revenue Fulcrum Therapeutics's revenue was reported to be $8.82 m in FY, 2020 Summary Investors excited about the . Address. Email. Fulcrum Therapeutics SCD. Fulcrum Therapeutics, Inc. recently announced the first patient has been dosed in REACH, a Phase 3 clinical trial designed to evaluate the safety and efficacy of losmapimod for the treatment of FSHD. Contact: Dee Smith Executive Director, Corporate Communications Fulcrum Therapeutics (202) 746-1324 . Developer contact. Following the live webcast, an archived replay . Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. Fulcrum Therapeutics annonce la preuve de concept pour FTX-6058 dans la drpanocytose s.. 05/12: Fulcrum Therapeutics prsentera les donnes initiales de l'essai de phase 1b du FTX-605.. 05/09: Fulcrum Therapeutics, Inc. annonce ses rsultats pour le premier trimestre clos le 31 m.. . It has developed a proprietary product engine that employs to identify and validate cellular drug targets that can modulate gene expression. This compares to loss of $0.66 per share a year ago. Fulcrum Therapeutics, Inc. will host a conference call and webcast today at 8:00 a.m. Identification No.) Fulcrum's two lead programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular . Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet need. Fulcrum Therapeutics has a 12-month low of $3.21 and a 12-month high of $33.10. fulcrum therapeutics, inc. 26 LANDSDOWNE STREET CAMBRIDGE MA 02139 Business Phone: 617-651-8851 SEC SIC CODE: 2834-PHARMACEUTICAL PREPARATIONS Recent SEC Filings Fulcrum's proprietary product engine identifies drug targets which can modulate gene expression to treat the known root cause of gene mis-expression. The stock has a market capitalization of $200.98 million, a PE ratio of -2.06 and a beta of 2.55. . Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that the Company granted nonstatutory stock options to new employees as inducement awards outside of the Company's 2019 Stock Incentive Plan. . Our approach to drug discovery and development is applicable across a large number of genetically defined diseases. . Fulcrum Therapeutics, Inc. (FULC Quick Quote FULC - Free Report) came out with a quarterly loss of $0.57 per share versus the Zacks Consensus Estimate of a loss of $0.64.This compares to loss of . At the very opening of the session, the stock price was $8.17 and reached a high price of $8.43, prior to closing the session it reached the value of $8.09. Join to connect . Fulcrum Therapeutics is a biotechnology company developing new medicines to deliver a new future to patients and their families by transforming gene regulation in disease. Actively observing the price movement in the last trading, the stock closed the session at $6.92, falling within a range of $6.63 and $7.955. Fulcrum Therapeutics, Inc. , which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $2.59 million for the quarter ended March 2022, missing the Zacks Consensus Estimate by 24.98%. Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet need. 02139-4216. Search FOX4KC WDAF-TV
Dec 6, 2021. About Fulcrum Therapeutics Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. here. Contact: REACH . Get Fulcrum Therapeutics Inc (FULC:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. Fulcrum Therapeutics share price went down by -28.9% last month. During the same period in the prior year, the business posted ($0.64) earnings per share. 26 Landsdowne Street. However, while Fulcrum may elect to update these forward-looking statements at some point in the future, Fulcrum specifically disclaims any obligation to do so. The 1-year high price for the company's stock is recorded $24.79 on 04/05/22, with the lowest value was $6.88 for the same time period, recorded on 05/10/22. Add to wishlist. Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Tel: 617-651-8851 Email: info@fulcrumtx.com About this app. CAMBRIDGE, Mass., July 05, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that the first patient has been dosed in REACH, a Phase 3 clinical trial designed to evaluate the safety and . We are applying our . . Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum Therapeutics is pioneering small molecule therapeutic approaches to gene regulation in neuromuscular genetically defined diseases. Shares of Fulcrum Therapeutics ( FULC 0.41%), an early clinical-stage biopharmaceutical company, are rocketing higher after an encouraging clinical trial readout. Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. CAMBRIDGE, Mass., July 05, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that the first patient has been dosed in REACH, a Phase 3 clinical trial designed to evaluate the safety and . support@medable.com . cambridge, mass., may 12, 2022 (globe newswire) -- fulcrum therapeutics, inc (nasdaq: fulc), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that it will be presenting two posters at the european hematology association (eha) hybrid congress which will Cambridge, Massachusetts : 02139 (Address of Principal Executive Offices) (Zip Code) Registrant's telephone number . On Thursday, April 7th, Robert J. Gould sold 5,631 shares of Fulcrum Therapeutics stock. we have a process in place the begins with RocketReach and ends with huge contact lists for our sales team..it probably saves Feedtrail about 3 months of work in terms of lead gathering. Fulcrum Therapeutics Inc. had a pretty Dodgy run when it comes to the market performance. - REACH is the first Phase 3 trial for this rare, progressive, and debilitating muscular disease -- Losmapimod is an oral small molecule that has the potential to be the first therapy to treat FSHD, the second most common form of muscular dystrophy -- U.S. Food and Drug Administration (FDA) granted Fast Track Designation in 2021 - CAMBRIDGE, Mass., July 05, 2022 (GLOBE NEWSWIRE . Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. This app is specifically intended for study participants in the Fulcrum 6058-scd-101 study only. Fulcrum Therapeutics, Inc. (FULC) delivered earnings and revenue surprises of 7.69% and 62.68%, respectively, for the quarter ended June 2021. Headquarters. cambridge, mass., july 05, 2022 (globe newswire) -- fulcrum therapeutics, inc. (nasdaq: fulc), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically. of Incorporation) . The stock touched a low price of $7.91.Recently in N 26 Landsdowne St. Cambridge, MA. Do the numbers hold clues to what lies ahead for . where she led the formation of new companies positioned to address areas of unmet need in . Easily apply. Fulcrum Therapeutics has a 12-month low of $3.21 and a 12-month high of $33.10. There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's . Contact: REACH . Fulcrum Therapeutics had a negative return on equity of 48.38% and a negative net margin of 529.15%. As of May 15th, there was short interest totalling 3,420,000 shares, a decline of 21.7% from the April 30th total of 4,370,000 shares. expand_more. The stock was sold at an average price of $24.02, for a total transaction of $135,256.62. All content is posted anonymously by employees working at Fulcrum Therapeutics. Fulcrum Therapeutics ( NASDAQ:FULC - Get Rating) 's stock had its "buy" rating reiterated by HC Wainwright in a research report issued on Friday, TipRanks reports. NASDAQ:FULC traded . The company's proprietary product engine, FulcrumSeek, identifies drug targets that can modulate gene expression to treat the known root cause of gene mis-expression. We are focused on improving the lives of patients with genetically defined diseases in areas of high unmet medical need. Distributed by Public, . cambridge, mass., june 10, 2022 (globe newswire) -- fulcrum therapeutics, inc. (nasdaq: fulc), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically.
Fulcrum Therapeutics has a 12 month low of $6.85 and a 12 month high of $33.10. Based on an average daily trading volume, of 733,700 shares, the short-interest ratio is presently 4.7 days. Contact: Investors: Stephanie Ascher Stern Investor Relations, Inc. stephanie.ascher@sternir.com 212-362-1200. . Contact Brynne directly Join to view full profile People also viewed . Fulcrum Therapeutics, Inc. (FULC) delivered earnings and revenue surprises of -1.59% and 24.98%, respectively, for the quarter ended March 2022. Corporate Profile. info. Credit Suisse Group lifted their price objective on Fulcrum Therapeutics from $30.00 to $35.00 and gave the stock an "outperform" rating in a research note on Friday, March 25th. Trust, Respect, Compassion and Integrity define who we are. Join the #FULcrew today.. Contact Email info@fulcrumtx.com Phone Number (617)651-8851 Fulcrum Therapeutics is a biotechnology company developing new medicines to deliver a new future to patients. 2. email. Above all we are champions for our patients. Fulcrum Therapeutics Inc. (FULC) is priced at $4.72 after the most recent trading session. Fulcrum Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware : 001-38978 : 47-4839948 (State or Other Jurisdiction. Fulcrum Therapeutics, Inc(R) announced clinical proof-of-concept data from the ongoing Phase 1b trial of FTX-6058 for the treatment of sickle cell disease. Do the numbers hold clues to what lies ahead for . . United States. Even though Fulcrum Therapeutics (NASDAQ:FULC) has lost US$304m market cap in last 7 days, shareholders are still up 42% over 1 year. We launched Fulcrum Therapeutics with a bold vision: To change the course of genetically defined diseases by treating them at their root cause. finance.yahoo.com - April 13 at 8:18 AM. Updated on. Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Get Rating) was the recipient of a large decline in short interest in the month of May. Media: Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in areas of. About Fulcrum Therapeutics. Posted. Fulcrum Therapeutics, Inc. (FULC) delivered earnings and revenue surprises of 18.18% and 119.38%, respectively, for the quarter ended March 2021. Apply for the Job in Manager, Clinical Data Management at Cambridge, MA. Install. Approximately 11.6% of . Contact: Dee Smith Executive Director, Corporate Communications Fulcrum Therapeutics (202) 746-1324. Their FULC stock forecasts range from $20.00 to $43.00. Name and Address of Reporting Person * Collins James J. Medical. Fulcrum Therapeutics - Losmapimod.
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet need. . Vice-President, Early Development. finance.yahoo.com - April 28 at 8:51 PM. The current opening is for a Director/Senior Director with a minimum of 10 years of Pharmaceutical / Biotech experience to lead our Toxicology function. Fulcrum Therapeutics Inc. published this content on 29 June 2022 and is solely responsible for the information contained therein. 0 . On average, they predict Fulcrum Therapeutics' share price to reach $31.57 in the next year. The webcast will be accessible through the Investor Relations section of Fulcrum's website at www.fulcrumtx.com. cambridge, mass., june 10, 2022 (globe newswire) -- fulcrum therapeutics, inc (nasdaq:fulc), a clinical stage biopharmaceutical company focused on improving the lives of patients with genetically.
Fulcrum Therapeutics Inc. had a pretty Dodgy run when it comes to the market performance. (IRS Employer. . He joined Fulcrum as chief operating officer in 2018, bringing over 20 years of industry experience, predominantly in the rare disease space. About Fulcrum Therapeutics . Fulcrum Therapeutics, Inc. (NASDAQ:NASDAQ:FULC) Q2 2021 Earnings Conference Call August 10, 2021 08:00 AM ET Company Participants Christi Waarich - Director, IR & Corporate. Latest Fulcrum Therapeutics Inc ( FULC) Stock News.
10 views, 3 likes, 0 loves, 0 comments, 0 shares, Facebook Watch Videos from Fulcrum Therapeutics: Ready to be a part of a company with a Bold Scientific Vision? Shares of NASDAQ . On Thursday, April 7th, Robert J. Gould sold 5,631 shares of Fulcrum Therapeutics stock.
Fulcrum Therapeutics ( NASDAQ:FULC - Get Rating) last posted its earnings results on Monday, May 9th. Our approach to drug discovery generates significant insights into disease biology and allows us to think creatively about the best way to modulate and balance gene expression. Initial data from the first subjects to receive a 6 mg dose of FTX-6058, an oral HbF inducer, showed a rapid and robust induction of HbF, and subjects achieved increases of up to 6.3% over . ET to discuss the Company's first quarter 2022 recent business highlights and financial results. The firm has a market capitalization of $312.08 million, a price-to-earnings ratio of -3.20 and a beta of 2.52. As of June 23, 2022, Fulcrum Therapeutics Inc had a $201.0 million market capitalization, compared to the Biotechnology & Medical Research median of $107.3 million. Fulcrum Therapeutics's next ex-dividend date is May 7, 2020.
Medable Inc. 1+ Downloads.
. 2022-06-30 - Amalgamated Bank has filed a 13F-HR form disclosing ownership of 3,324 shares of Fulcrum Therapeutics Inc (US:FULC) with total holdings valued at $79,000 USD as of 2022-03-31. Glassdoor gives you an inside look at what it's like to work at Fulcrum Therapeutics, including salaries, reviews, office photos, and more. Fulcrum's proprietary product engine identifies drug targets which can modulate gene expression to treat the known root cause of . 02139-4216. Fulcrum Therapeutics. Morgan . United States. This suggests a possible upside of 544.3% from the stock's current price. Contact: Dee Smith Executive Director, Corporate Communications Fulcrum Therapeutics (202) 746-1324 Tired of arriving late to the Big Returns Party? June 23, 2020. Contact: REACH . Data safety. Fulcrum Therapeutics Inc. (NASDAQ:FULC) shares, rose in value on Thursday, 06/02/22, with the stock price up by 8.67% to the previous day's close as strong demand from buyers drove the stock to $7.52. The stock has a market capitalization of $200.98 million, a PE ratio of -2.06 and a beta of 2.55. Fulcrum Therapeutics Inc only started trading within the last year so does not have performance data for the past year. Its product candidate, losmapimod, is a small molecule that was developed for the treatment of FSHD, a muscle-wasting disorder that . Accounting Manager at Fulcrum Therapeutics Boston, Massachusetts, United States 363 connections. Fulcrum . Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum . Fulcrum Therapeutics, Inc. (FULC) came out with a quarterly loss of $0.60 per share versus the Zacks Consensus Estimate of a loss of $0.65. Fulcrum Therapeutics Employees: 122 | Industry: Biotechnology, Gene Regulation, Science and Engineering | Founded: 2016 . About Fulcrum Therapeutics Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Bryan Stuart was named president and chief executive officer of Fulcrum Therapeutics in March 2021. Address. The company reported ($0.64) earnings per share (EPS) for the . Contact: REACH trial information clinicaltrials@fulcrumtx.com Investors Stephanie Ascher Stern Investor Relations, Inc. stephanie.ascher@sternir.com 212-362-1200 Media Dee Smith 26 Landsdowne St. Cambridge, MA. We have developed a rigorous assessment and selection process to determine which of the approximately 7,000 rare, genetically defined diseases we intend to evaluate in drug target identification activities. Do the numbers hold clues to what lies ahead for the . Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. The randomized, double-blind, placebo-controlled, multi-national Phase 3 trial will enroll approximately 230 adults at over 30 sites in North . Issuer Name and Ticker or Trading Symbol Fulcrum Therapeutics, Inc. [FULC] 5. Relationship of Reporting Person(s) to Issuer . 8 Wall Street research analysts have issued 12 month price objectives for Fulcrum Therapeutics' stock. Fulcrum Therapectics to develop new medicines to deliver a new future for patients and their families by transforming gene regulation in disease. Fulcrum Therapeutics, Inc. 26 Landsdowne Street Cambridge, MA 02139. About Fulcrum Therapeutics. View Top Employees from Fulcrum Therapeutics Find contact info for Fulcrum Therapeutics employees The next quarterly earnings date for Fulcrum Therapeutics is scheduled on August 10, 2022.
Cambridge, MA. The 1-year high price for the company's stock is recorded $24.79 on 04/05/22, with the lowest value was $3.21 for the same time period, recorded on 06/10/22. This is the Fulcrum Therapeutics company profile. We can divert our attention to . Everyone. The company develops a proprietary product engine that employs to identify and validate cellular drug targets that can modulate gene expression. and may address the renin-angiotensin system imbalance that is believed to contribute to key morbidities in COVID-19 patients. They currently have a . The shares were sold at an average price of $24.02, for a total value of $135,256.62. PepGen Appoints Michelle Mellion, M.D., as Senior Vice President, Head of Clinical Development. Fulcrum's two lead programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral . arrow_forward. Fulcrum Therapeutics Office Locations Fulcrum Therapeutics has an office in Cambridge Open Map View Cambridge, MA, US (HQ) 26 Landsdowne St Show all (1) Report incorrect company information Fulcrum Therapeutics Financials and Metrics Fulcrum Therapeutics Revenue Fulcrum Therapeutics's revenue was reported to be $8.82 m in FY, 2020 Summary Investors excited about the . Address. Email. Fulcrum Therapeutics SCD. Fulcrum Therapeutics, Inc. recently announced the first patient has been dosed in REACH, a Phase 3 clinical trial designed to evaluate the safety and efficacy of losmapimod for the treatment of FSHD. Contact: Dee Smith Executive Director, Corporate Communications Fulcrum Therapeutics (202) 746-1324 . Developer contact. Following the live webcast, an archived replay . Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. Fulcrum Therapeutics annonce la preuve de concept pour FTX-6058 dans la drpanocytose s.. 05/12: Fulcrum Therapeutics prsentera les donnes initiales de l'essai de phase 1b du FTX-605.. 05/09: Fulcrum Therapeutics, Inc. annonce ses rsultats pour le premier trimestre clos le 31 m.. . It has developed a proprietary product engine that employs to identify and validate cellular drug targets that can modulate gene expression. This compares to loss of $0.66 per share a year ago. Fulcrum Therapeutics, Inc. will host a conference call and webcast today at 8:00 a.m. Identification No.) Fulcrum's two lead programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular . Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet need. Fulcrum Therapeutics has a 12-month low of $3.21 and a 12-month high of $33.10. fulcrum therapeutics, inc. 26 LANDSDOWNE STREET CAMBRIDGE MA 02139 Business Phone: 617-651-8851 SEC SIC CODE: 2834-PHARMACEUTICAL PREPARATIONS Recent SEC Filings Fulcrum's proprietary product engine identifies drug targets which can modulate gene expression to treat the known root cause of gene mis-expression. The stock has a market capitalization of $200.98 million, a PE ratio of -2.06 and a beta of 2.55. . Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that the Company granted nonstatutory stock options to new employees as inducement awards outside of the Company's 2019 Stock Incentive Plan. . Our approach to drug discovery and development is applicable across a large number of genetically defined diseases. . Fulcrum Therapeutics, Inc. (FULC Quick Quote FULC - Free Report) came out with a quarterly loss of $0.57 per share versus the Zacks Consensus Estimate of a loss of $0.64.This compares to loss of . At the very opening of the session, the stock price was $8.17 and reached a high price of $8.43, prior to closing the session it reached the value of $8.09. Join to connect . Fulcrum Therapeutics is a biotechnology company developing new medicines to deliver a new future to patients and their families by transforming gene regulation in disease. Actively observing the price movement in the last trading, the stock closed the session at $6.92, falling within a range of $6.63 and $7.955. Fulcrum Therapeutics, Inc. , which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $2.59 million for the quarter ended March 2022, missing the Zacks Consensus Estimate by 24.98%. Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet need. 02139-4216. Search FOX4KC WDAF-TV
Dec 6, 2021. About Fulcrum Therapeutics Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. here. Contact: REACH . Get Fulcrum Therapeutics Inc (FULC:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. Fulcrum Therapeutics share price went down by -28.9% last month. During the same period in the prior year, the business posted ($0.64) earnings per share. 26 Landsdowne Street. However, while Fulcrum may elect to update these forward-looking statements at some point in the future, Fulcrum specifically disclaims any obligation to do so. The 1-year high price for the company's stock is recorded $24.79 on 04/05/22, with the lowest value was $6.88 for the same time period, recorded on 05/10/22. Add to wishlist. Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Tel: 617-651-8851 Email: info@fulcrumtx.com About this app. CAMBRIDGE, Mass., July 05, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that the first patient has been dosed in REACH, a Phase 3 clinical trial designed to evaluate the safety and . We are applying our . . Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum Therapeutics is pioneering small molecule therapeutic approaches to gene regulation in neuromuscular genetically defined diseases. Shares of Fulcrum Therapeutics ( FULC 0.41%), an early clinical-stage biopharmaceutical company, are rocketing higher after an encouraging clinical trial readout. Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. CAMBRIDGE, Mass., July 05, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that the first patient has been dosed in REACH, a Phase 3 clinical trial designed to evaluate the safety and . support@medable.com . cambridge, mass., may 12, 2022 (globe newswire) -- fulcrum therapeutics, inc (nasdaq: fulc), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that it will be presenting two posters at the european hematology association (eha) hybrid congress which will Cambridge, Massachusetts : 02139 (Address of Principal Executive Offices) (Zip Code) Registrant's telephone number . On Thursday, April 7th, Robert J. Gould sold 5,631 shares of Fulcrum Therapeutics stock. we have a process in place the begins with RocketReach and ends with huge contact lists for our sales team..it probably saves Feedtrail about 3 months of work in terms of lead gathering. Fulcrum Therapeutics Inc. had a pretty Dodgy run when it comes to the market performance. - REACH is the first Phase 3 trial for this rare, progressive, and debilitating muscular disease -- Losmapimod is an oral small molecule that has the potential to be the first therapy to treat FSHD, the second most common form of muscular dystrophy -- U.S. Food and Drug Administration (FDA) granted Fast Track Designation in 2021 - CAMBRIDGE, Mass., July 05, 2022 (GLOBE NEWSWIRE . Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. This app is specifically intended for study participants in the Fulcrum 6058-scd-101 study only. Fulcrum Therapeutics, Inc. (FULC) delivered earnings and revenue surprises of 7.69% and 62.68%, respectively, for the quarter ended June 2021. Headquarters. cambridge, mass., july 05, 2022 (globe newswire) -- fulcrum therapeutics, inc. (nasdaq: fulc), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically. of Incorporation) . The stock touched a low price of $7.91.Recently in N 26 Landsdowne St. Cambridge, MA. Do the numbers hold clues to what lies ahead for . where she led the formation of new companies positioned to address areas of unmet need in . Easily apply. Fulcrum Therapeutics has a 12-month low of $3.21 and a 12-month high of $33.10. There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's . Contact: REACH . Fulcrum Therapeutics had a negative return on equity of 48.38% and a negative net margin of 529.15%. As of May 15th, there was short interest totalling 3,420,000 shares, a decline of 21.7% from the April 30th total of 4,370,000 shares. expand_more. The stock was sold at an average price of $24.02, for a total transaction of $135,256.62. All content is posted anonymously by employees working at Fulcrum Therapeutics. Fulcrum Therapeutics ( NASDAQ:FULC - Get Rating) 's stock had its "buy" rating reiterated by HC Wainwright in a research report issued on Friday, TipRanks reports. NASDAQ:FULC traded . The company's proprietary product engine, FulcrumSeek, identifies drug targets that can modulate gene expression to treat the known root cause of gene mis-expression. We are focused on improving the lives of patients with genetically defined diseases in areas of high unmet medical need. Distributed by Public, . cambridge, mass., june 10, 2022 (globe newswire) -- fulcrum therapeutics, inc. (nasdaq: fulc), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically.
Fulcrum Therapeutics has a 12 month low of $6.85 and a 12 month high of $33.10. Based on an average daily trading volume, of 733,700 shares, the short-interest ratio is presently 4.7 days. Contact: Investors: Stephanie Ascher Stern Investor Relations, Inc. stephanie.ascher@sternir.com 212-362-1200. . Contact Brynne directly Join to view full profile People also viewed . Fulcrum Therapeutics, Inc. (FULC) delivered earnings and revenue surprises of -1.59% and 24.98%, respectively, for the quarter ended March 2022. Corporate Profile. info. Credit Suisse Group lifted their price objective on Fulcrum Therapeutics from $30.00 to $35.00 and gave the stock an "outperform" rating in a research note on Friday, March 25th. Trust, Respect, Compassion and Integrity define who we are. Join the #FULcrew today.. Contact Email info@fulcrumtx.com Phone Number (617)651-8851 Fulcrum Therapeutics is a biotechnology company developing new medicines to deliver a new future to patients. 2. email. Above all we are champions for our patients. Fulcrum Therapeutics Inc. (FULC) is priced at $4.72 after the most recent trading session. Fulcrum Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware : 001-38978 : 47-4839948 (State or Other Jurisdiction. Fulcrum Therapeutics, Inc(R) announced clinical proof-of-concept data from the ongoing Phase 1b trial of FTX-6058 for the treatment of sickle cell disease. Do the numbers hold clues to what lies ahead for . . United States. Even though Fulcrum Therapeutics (NASDAQ:FULC) has lost US$304m market cap in last 7 days, shareholders are still up 42% over 1 year. We launched Fulcrum Therapeutics with a bold vision: To change the course of genetically defined diseases by treating them at their root cause. finance.yahoo.com - April 13 at 8:18 AM. Updated on. Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Get Rating) was the recipient of a large decline in short interest in the month of May. Media: Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in areas of. About Fulcrum Therapeutics. Posted. Fulcrum Therapeutics, Inc. (FULC) delivered earnings and revenue surprises of 18.18% and 119.38%, respectively, for the quarter ended March 2021. Apply for the Job in Manager, Clinical Data Management at Cambridge, MA. Install. Approximately 11.6% of . Contact: Dee Smith Executive Director, Corporate Communications Fulcrum Therapeutics (202) 746-1324. Their FULC stock forecasts range from $20.00 to $43.00. Name and Address of Reporting Person * Collins James J. Medical. Fulcrum Therapeutics - Losmapimod.
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet need. . Vice-President, Early Development. finance.yahoo.com - April 28 at 8:51 PM. The current opening is for a Director/Senior Director with a minimum of 10 years of Pharmaceutical / Biotech experience to lead our Toxicology function. Fulcrum Therapeutics Inc. published this content on 29 June 2022 and is solely responsible for the information contained therein. 0 . On average, they predict Fulcrum Therapeutics' share price to reach $31.57 in the next year. The webcast will be accessible through the Investor Relations section of Fulcrum's website at www.fulcrumtx.com. cambridge, mass., june 10, 2022 (globe newswire) -- fulcrum therapeutics, inc (nasdaq:fulc), a clinical stage biopharmaceutical company focused on improving the lives of patients with genetically.
Fulcrum Therapeutics Inc. had a pretty Dodgy run when it comes to the market performance. (IRS Employer. . He joined Fulcrum as chief operating officer in 2018, bringing over 20 years of industry experience, predominantly in the rare disease space. About Fulcrum Therapeutics . Fulcrum Therapeutics, Inc. (NASDAQ:NASDAQ:FULC) Q2 2021 Earnings Conference Call August 10, 2021 08:00 AM ET Company Participants Christi Waarich - Director, IR & Corporate. Latest Fulcrum Therapeutics Inc ( FULC) Stock News.
10 views, 3 likes, 0 loves, 0 comments, 0 shares, Facebook Watch Videos from Fulcrum Therapeutics: Ready to be a part of a company with a Bold Scientific Vision? Shares of NASDAQ . On Thursday, April 7th, Robert J. Gould sold 5,631 shares of Fulcrum Therapeutics stock.